![](https://www.canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBY289IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--485862da6d23b52e9ee2f09a0f1a14736779e719/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/marinus-logo-revised-website.fw_.png)
Marinus Pharmaceuticals
Marinus is creating a new class of neurologic drugs that may revolutionize the treatment of epilepsy in women and infants.
Website
www.marinuspharma.comPartner
Stephen BlochInvestment
Series A
Marinus is creating a new class of neurologic drugs that may revolutionize the treatment of epilepsy in women and infants.
Series A